Compile Data Set for Download or QSAR
Report error Found 190 Enz. Inhib. hit(s) with all data for entry = 9488
TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470468(US10815213, Example 130 | 1-[(3R)-1-acryloylpiperi...)
Affinity DataIC50: 0.170nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM303543(US10138229, Example 54 | US10266513, Example 127 |...)
Affinity DataIC50: 0.180nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377842(1-[(3S)-1-acryloyl piperidin-3-yl]-5-amino-3-[4-(2...)
Affinity DataIC50: 0.25nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377707(US10266513, Example 2 | US10266513, Example 3 | 5-...)
Affinity DataIC50: 0.370nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377839(5-amino-3-[4-(4-chlorophenoxy)phenyl]-1-{(3R)-1-[(...)
Affinity DataIC50: 0.380nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470355(US10815213, Example 17 | (R)-5-amino-1-(1-cyanopip...)
Affinity DataIC50: 0.400nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377831(5-amino-1-(1-cyanopiperidin-3-yl)-3-[4-(phenylthio...)
Affinity DataIC50: 0.400nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377850(5-amino-1-{(3R)-1-[(2E)-4,4-difluorobut-2-enoyl]pi...)
Affinity DataIC50: 0.410nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377734(5-amino-1-(1-cyanopiperidin-3-yl)-3-[4-(3-fluoro-4...)
Affinity DataIC50: 0.430nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377754(US10266513, Example 48 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 0.440nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377827(5-amino-1-[(3R*,6S*)-1-cyano-6-methylpiperidin-3-y...)
Affinity DataIC50: 0.460nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470491(US10815213, Example 153 | 1-[(3R)-1-acryloylpiperi...)
Affinity DataIC50: 0.480nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377778(US10266513, Example 72 | (R)-5-amino-3-(4-(2-chlor...)
Affinity DataIC50: 0.540nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377775(US10266513, Example 69 | (R)-5-amino-1-(1-cyanopip...)
Affinity DataIC50: 0.600nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM50512857(CHEMBL4456283 | US10815213, Example 15)
Affinity DataIC50: 0.640nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470493(US10815213, Example 155 | 5-amino-3-{4-[(5-chloro-...)
Affinity DataIC50: 0.700nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377830(5-amino-3-{4-[(4-chlorophenyl)thio]phenyl}-1-(1-cy...)
Affinity DataIC50: 0.740nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377749(US10266513, Example 43 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 0.770nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470375(US10815213, Example 37 | (R)-5-amino-3-[4-(2-chlor...)
Affinity DataIC50: 0.790nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377751(US10266513, Example 45 | 5-amino-3-[4-(2-chloro-5-...)
Affinity DataIC50: 0.810nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377780(5-amino-1-(1-cyanopiperidn-3-yl)-3-[4-(2-fluoroben...)
Affinity DataIC50: 0.810nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377725(US10266513, Example 19 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 1nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377726(5-amino-3-[4-(4-chloro-2-methylphenoxy)phenyl]-1-(...)
Affinity DataIC50: 1nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377734(5-amino-1-(1-cyanopiperidin-3-yl)-3-[4-(3-fluoro-4...)
Affinity DataIC50: 1nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377780(5-amino-1-(1-cyanopiperidn-3-yl)-3-[4-(2-fluoroben...)
Affinity DataIC50: 1nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377835(5-amino-1-{(3R)-1-[(2E)-4-hydroxybut-2-enoyl]piper...)
Affinity DataIC50: 1nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377745(US10266513, Example 39 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 1.10nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470470(US10815213, Example 132 | 5-amino-3-[4-(4-chloroph...)
Affinity DataIC50: 1.10nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377748(US10266513, Example 42 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 1.20nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377760(US10266513, Example 54 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 1.20nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377841(5-amino-3-[4-(4-chlorophenoxy)phenyl]-1-{(3R)-1-[(...)
Affinity DataIC50: 1.20nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377867(1-[(3R)-1-acryloyl piperidin-3-yl]-5-amino-3-(4-{[...)
Affinity DataIC50: 1.20nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377722(5-amino-1-(1-cyanopiperidin-3-yl)-3-[4-(3,4-dimeth...)
Affinity DataIC50: 1.28nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377731(US10266513, Example 26 | US10266513, Example 27 | ...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377762(US10266513, Example 56 | 5-amino-3-[4-(2-chlorophe...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377793(US10266513, Example 87 | 5-Amino-3-(4-benzoyl-phen...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377832(1-[(3S)-1-acryloyl piperidin-3-yl]-5-amino-3-(4-ph...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470495(US10815213, Example 157 | 1-[(3R)-1-acryloylpiperi...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470497(US10815213, Example 159 | 5-amino-3-{4-[(5-chlorop...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377869(5-amino-1-{(3R)-1-[(2E)-4,4-difluorobut-2-enoyl]pi...)
Affinity DataIC50: 1.30nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377707(US10266513, Example 2 | US10266513, Example 3 | 5-...)
Affinity DataIC50: 1.40nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377783(5-amino-1-(1-cyanopiperidin-3-yl)-3-[4-(3-fluorobe...)
Affinity DataIC50: 1.40nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470494(US10815213, Example 156 | 5-amino-3-{4-[(5-chloro-...)
Affinity DataIC50: 1.40nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377746(US10266513, Example 40 | 5-amino-3-[4-(4-chloro-3-...)
Affinity DataIC50: 1.5nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM470490(US10815213, Example 152 | 5-amino-1-{(3R)-1-[(2E)-...)
Affinity DataIC50: 1.5nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377753(US10266513, Example 47 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 1.60nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377741(US10266513, Example 37 | US10266513, Example 36 | ...)
Affinity DataIC50: 1.70nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377759(US10266513, Example 53 | 5-amino-3-[4-(3-chlorophe...)
Affinity DataIC50: 1.70nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377756(US10266513, Example 50 | 5-amino-1-(1-cyanopiperid...)
Affinity DataIC50: 1.80nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pfizer

US Patent
LigandPNGBDBM377764(US10266513, Example 58 | 5-amino-3-[4-(3-chloro-4-...)
Affinity DataIC50: 1.80nMAssay Description:BTK: TR-FRET LanthaScreen assays were performed by incubating a dilution series of inhibitor concentrations with 50 μM ATP, 100 nM FAM-Srctide p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 190 total ) | Next | Last >>
Jump to: